Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Oligoprogressive 1

Interventions

pembrolizumab 33Carboplatin 18Cisplatin 15Nivolumab 14Pemetrexed 12Paclitaxel 12Ipilimumab 11atezolizumab 10Gemcitabine 10venetoclax 9Radiotherapy 9Docetaxel 9durvalumab 8Cyclophosphamide 8fludarabine 7Specimen Handling 7Biopsy 7Bevacizumab 7tislelizumab 6enzalutamide 6Trastuzumab 6Practice Guidelines as Topic 6Cetuximab 6tazemetostat 5fludarabine phosphate 5Surveys and Questionnaires 5Standard of Care 5Radiosurgery 5Magnetic Resonance Spectroscopy 5Injections 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × DEAE-Dextran × 90 days × Clear all
NCT05846659 2026-05-15

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

ImmuneSensor Therapeutics Inc.

Phase 2 Terminated
16 enrolled 13 charts

Oligoprogressive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡